Eric J. Duncavage, MD

Research Interests

Dr. Duncavage is a professor in the Department of Pathology and Immunology at WashU Medicine in St. Louis, MO and is a member of the Siteman Cancer Center. He currently serves as the director of Genomic and  Molecular Pathology Division and is the former director of the hematopathology section.  Dr. Duncavage is board certified in anatomic pathology, clinical pathology, molecular pathology, hematopathology, and clinical informatics.  His clinical practice includes sign out of blood, bone marrow, lymph nodes, and molecular diagnostics cases. As the director of molecular oncology, Dr. Duncavage oversees molecular testing in the regulated CAP/CLIA environment including the design and implementation of cutting-edge assays such as MyeloSeq^®-HD, a first to market UMI-based NGS assay for the detection of measurable residual disease in myeloid neoplasms, and ChromoSeq^®, a first to market comprehensive WGS-based assay for myeloid neoplasms. Dr. Duncavage’s research is focused on understanding the biology of myeloid neoplasms such as MDS and AML and developing better clinical diagnostics using sequencing-based approaches. This work is funded through several NIH and foundation awards and has resulted in multiple high-profile publications.